NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing therapeutics based on its ...

The nation may be in a mental health crisis, with many people from the young to the old suffering from depression, anxiety, PTSD and suicidal ideation. The latter is particularly true for patients ...

IND builds on previously-published, preliminary evidence of efficacy Filing is supported by robust manufacturing, pre-clinical and clinical data already reviewed by FDA for NRX-101 associated with ...

Ketamine, an NMDA blocker, was highly effective in Bipolar subgroup (p<0.001) NRx plans to present the data to FDA with a goal of identifying a path to an NDA RADNOR, Pa., Sept. 15, 2023 /PRNewswire/ ...

Scientists have zeroed in on a critical weak spot behind a rare but devastating brain autoimmune disorder often known as ...

Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...

Researchers at Zhejiang University, China, have explored mechanisms for the sustained antidepressant effects of ketamine, suggesting that a direct N-methyl-D-aspartate receptor (NMDAR) blockade might ...

In February 2025, Ryan Alto, a 48-year-old from California, developed what seemed like a routine flu. He had a headache, body aches, and general fatigue, but within hours of driving himself to the ...

When lithium or valproate aren't enough, ‘add-on’ treatments like atypical antipsychotics can help. Discover 7 options to discuss with your doctor.